Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity

Author:

Hamid Megat H. B. A.ORCID,Cespedes Pablo F.ORCID,Jin Chen,Chen Ji-Li,Gileadi UziORCID,Antoun Elie,Liang ZhuORCID,Gao FeiORCID,Teague Renuka,Manoharan Nikita,Maldonado-Perez David,Khalid-Alham Nasullah,Cerundolo Lucia,Ciaoca Raul,Hester Svenja S.,Pinto-Fernández Adán,Draganov Simeon D.,Vendrell Iolanda,Liu Guihai,Yao Xuan,Kvalvaag Audun,Dominey-Foy Delaney C. C.ORCID,Nanayakkara CharunyaORCID,Kanellakis NikolaosORCID,Chen Yi-LingORCID,Waugh Craig,Clark Sally-AnnORCID,Clark Kevin,Sopp Paul,Rahman Najib M.ORCID,Verrill Clare,Kessler Benedikt M.ORCID,Ogg Graham,Fernandes Ricardo A.ORCID,Fisher RomanORCID,Peng Yanchun,Dustin Michael L.ORCID,Dong TaoORCID

Abstract

AbstractCancer remains one of the leading causes of mortality worldwide, leading to increased interest in utilizing immunotherapy strategies for better cancer treatments. In the past decade, CD103+ T cells have been associated with better clinical prognosis in patients with cancer. However, the specific immune mechanisms contributing toward CD103-mediated protective immunity remain unclear. Here, we show an unexpected and transient CD61 expression, which is paired with CD103 at the synaptic microclusters of T cells. CD61 colocalization with the T cell antigen receptor further modulates downstream T cell antigen receptor signaling, improving antitumor cytotoxicity and promoting physiological control of tumor growth. Clinically, the presence of CD61+ tumor-infiltrating T lymphocytes is associated with improved clinical outcomes, mediated through enhanced effector functions and phenotype with limited evidence of cellular exhaustion. In conclusion, this study identified an unconventional and transient CD61 expression and pairing with CD103 on human immune cells, which potentiates a new target for immune-based cellular therapies.

Publisher

Springer Science and Business Media LLC

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Taking down tumors takes atypical integrins;Science Signaling;2024-04-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3